MedPath

ME Therapeutics Initiates Efficacy Testing of mRNA Cancer Therapies Developed with NanoVation Therapeutics

  • ME Therapeutics has begun efficacy testing of its first two mRNA formulations developed in collaboration with NanoVation Therapeutics, targeting myeloid cells for cancer treatment.
  • NanoVation's long-circulating lipid nanoparticle (lcLNP) technology is designed to enhance the delivery of nucleic acids to immune cells, improving therapeutic precision.
  • The rapid development of these mRNA formulations highlights the potential of mRNA therapeutics for quickly addressing cancer and other diseases.
  • Initial studies aim to deepen the understanding of mRNA delivery's therapeutic potential to myeloid cells in combating cancer, marking a step forward in immuno-oncology.
ME Therapeutics Holdings Inc., a biotechnology company focused on immuno-oncology, has commenced efficacy testing of its initial mRNA formulations in collaboration with NanoVation Therapeutics Inc. The partnership leverages NanoVation's lipid nanoparticle (LNP) technologies to enhance the precision and efficacy of myeloid cell-delivered mRNA therapeutics for potential cancer treatments.

Strategic Collaboration and Technology

The collaboration between ME Therapeutics and NanoVation Therapeutics aims to exploit NanoVation's next-generation lipid nanoparticle platforms, which are engineered for efficient nucleic acid delivery to various tissues. NanoVation's long-circulating LNP (lcLNP) technology is specifically designed to target immune cells, optimizing its delivery for therapeutic effect. This technology underpins multiple RNA modality programs.

CEO's Perspective

Salim Dhanji, chief executive officer of ME Therapeutics, emphasized the speed of development, stating, "The speed at which we were able to go from announcing our research collaboration to having a testable drug demonstrates the potential of mRNA as a rapidly developable therapeutic modality to potentially treat cancer and other diseases." He further added, "These initial studies will increase our understanding of the therapeutic potential of mRNA delivery to myeloid cells for the treatment of cancer."

Myeloid Enhancement Therapeutics Focus

ME Therapeutics, based in Vancouver, is dedicated to discovering and developing novel immuno-oncology therapeutics. The company's primary focus is on counteracting the suppressive effects of myeloid cells to bolster anti-cancer immunity.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Emiltatug Ledadotin (XMT-1660) Shows Promise in Phase 1 Trial, Receives FDA Fast Track for Advanced Breast Cancer

Mersana Therapeutics' Emiltatug Ledadotin (XMT-1660) demonstrates a favorable safety profile in a Phase 1 trial with no Grade 4 or 5 treatment-related adverse events.

FDA Approvals Expand Initial Treatment Options for Multiple Myeloma

The FDA has approved new treatment options for newly diagnosed multiple myeloma patients, including daratumumab for transplant-eligible patients and isatuximab for those not eligible for a transplant. These approvals are based on clinical trials showing improved outcomes with four-drug regimens.

Merck and Moderna Launch Phase 3 Trial of mRNA-4157 plus Pembrolizumab in NSCLC

Merck and Moderna have initiated a Phase 3 clinical trial (INTerpath-009) to assess mRNA-4157 in combination with pembrolizumab for NSCLC.

Moderna and MSD Launch Phase III Trial of mRNA-4157 Plus Keytruda for NSCLC

Moderna and MSD have initiated a Phase III clinical trial, INTerpath-009, to evaluate mRNA-4157 (V940) in combination with Keytruda for non-small cell lung cancer (NSCLC).

Merck and Moderna Launch Phase 3 Trial of V940 (mRNA-4157) with Keytruda in NSCLC

Merck and Moderna have initiated a Phase 3 trial (INTerpath-009) to evaluate V940 (mRNA-4157) combined with Keytruda in NSCLC patients.

Merck and Moderna Advance mRNA-Based Cancer Therapy in Phase 3 Lung Cancer Trial

Merck and Moderna have initiated a Phase 3 trial (INTerpath-009) to evaluate V940 (mRNA-4157) combined with KEYTRUDA in resected Stage II-IIIB NSCLC patients.

NIH Launches myeloMATCH Trial to Personalize Treatment for Myeloid Cancers

The National Institutes of Health (NIH) has initiated the myeloMATCH clinical trial to evaluate precision medicine approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

NIH Initiates Precision Medicine Trial for Myeloid Cancers

The National Institutes of Health (NIH) has launched a precision medicine clinical trial focusing on acute myeloid leukemia and myelodysplastic syndromes.

NIH Launches myeloMATCH Precision Medicine Trial for Myeloid Cancers

The NIH's myeloMATCH trial aims to match AML and MDS patients to targeted treatments based on their cancer's genetic profile, enhancing precision medicine.

WestGene's mRNA Cancer Vaccine WGc-043 Receives Dual IND Approvals for EBV-Related Cancers

WestGene's WGc-043, an mRNA therapeutic cancer vaccine, has received IND approvals from both China's NMPA and the US FDA, marking a global first for EBV-related cancers.

Reference News

[1]
ME Therapeutics to begin testing of first mRNA formulations from NanoVation ... - Pharmabiz.com
pharmabiz.com · Sep 20, 2024

ME Therapeutics starts efficacy testing of first two mRNA formulations from collaboration with NanoVation Therapeutics, ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy